Daniel Grau appointed as president of Heptares
Daniel Grau has been appointed as president of Heptares Therapeutics, a specialist in G-protein-coupled receptors.
Mr Grau has been a senior advisor to Heptares since 2010 and focused on business development and corporate strategy.
In his role as president he will now have broad responsibilities for corporate and commercial development, reporting to chief executive Malcolm Weir.
Previously he served as president and chief executive of Cortria Corporation, chief operating officer of CombinatoRx, and as a business consultant to Pharmacia Corporation.
He earned his BA from Davidson College and holds an MPhil from Yale University.
Malcolm Weir, chief executive of Heptares, said: “Dan’s leadership in corporate and commercial development will be increasingly valuable as Heptares’ pipeline progresses and as partnerships organise around defined regions of GPCR target space.”
Grau said: “Internally, we are concentrating on serious neurological and metabolic disorders and advancing programmes on high-value targets that are clinically validated, but for which no small molecule medicines exist.
“I’m very excited to join the team and look forward to helping build the company.”
AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics …
Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan …